ATP binding cassette subfamily C member 3Genealiases: ABC31 · EST90757 · MLP2 · MOAT-D · MRP3 · cMOAT2
Q-omics provides the consensus-scored ABCC3 profile across patient tissues and cancer cell-line models. ABCC3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ABCC3 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, ABCC3 protein abundance shows 23,324 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight UVM, KIRC, and LUAD as cancer lineages where ABCC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABCC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABCC3 survival associations across molecular data types. ABCC3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABCC3 RNA expression–survival associations across cancer types. High ABCC3 expression shows unfavorable associations in UVM, HNSC, LGG and PAAD, but favorable associations in BLCA and SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for ABCC3 RNA expression.
This table summarizes ABCC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ABCC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABCC3 shows lower tumor expression in KICH and COAD and higher tumor expression in KIRC, KIRP, THCA and LUAD. The KIRC box plot shows higher ABCC3 RNA expression in tumor versus normal tissue (log2 FC = +2.718, t-test p < 0.001).
This table shows molecular features associated with ABCC3 in patient tissues and cancer cell lines. In patient samples, ABCC3 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ABCC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
